NCT00945490已完成3 期
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 2
- 主要终点
- American Urological Association Symptom Index (AUASI)
研究概览
简要总结
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Provide signed informed consent prior to enrolment in the study
- •Prostate Volume ≥ 30 mL ≤ 70 mL
- •Qmax < 15 mL/sec based on a minimum void of 125 mL
- •Agree not to use any other approved or experimental BPH or OAB medication anytime during the study
排除标准
- •History of illness or condition that may interfere with study or endanger subject
- •Use of prescribed medications that may interfere with study or endanger subject
- •Presence of a median lobe of the prostate
- •Previous surgery or MIST for treatment of BPH
- •Post-void residual urine volume > 200 mL
- •PSA ≥ 10 ng/mL; prostate cancer must be ruled out (negative biopsy) for PSA ≥ 4 ng/mL
- •Participation in a study of any investigational drug or device within the previous 90 days
- •Prostate cancer
研究组 & 干预措施
NX-1207
Experimental
干预措施: NX-1207 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
American Urological Association Symptom Index (AUASI)
时间窗: 365 days
次要结局
- Peak urine flow rate (Qmax)(180 days)
- American Urological Association Symptom Index (AUASI)(270 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)MPS IV ANCT01275066BioMarin Pharmaceutical177
撤回
1 期
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHLCLL/SLLNHLNCT05365100BioNova Pharmaceuticals (Shanghai) LTD.
已完成
不适用
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyNCT01049399Noscira SA146
已完成
3 期
Safety and Efficacy of Bronchitol in BronchiectasisBronchiectasisNCT00277537Syntara354
终止
1 期
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesNon Hodgkin LymphomaDiffuse Large B Cell LymphomaB-cell LymphomaMantle Cell LymphomaFollicular LymphomaNCT05611853BioNova Pharmaceuticals (Shanghai) LTD.9